Treatment of heart failure with preserved ejection fraction with combination of western medicine and Yangyin Shuxin prescription: a single-center, single-blind, randomized, controlled clinical trial

The clinical evaluation research of intervention of integrative traditional chinese and western medicine in heart failure with preserved ejection fraction

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030921

Enrollment

Unknown

Registered

2020-03-17

Start date

2018-01-01

Completion date

Unknown

Last updated

2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure with preserved ejection fraction

Interventions

Experimental group:Western Medicin + Yangyin Shuxin prescription

Control Group:Western Medicine

Health Group:None

Eligibility

Sex/Gender

All

Age

18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Symptoms±Signs of heart failure; LVEF>=45%; LVH/LAE/diastolic dysfunction 2. Aged 18 to 79 years; 3. NYHA classification I to III; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. ACS; 2. Aortic Dissection; 3. Fatal arrhythmia; 4. Acute Heart Failure; 5. Hypertension that cannot be controlled well; 6. Atrial fibrillation/Atrial flutter; 7. Advanced atrioventricular block; 8. Pericardial Diseases; 9. Valvular Disease; 10. Cardiomyopathy; 11. pulmonary embolism; 12. PAH; 13. Stroke in the past 3 months/Unfavorable unilateral limb movements due to Stroke; 14. Mental disease; 15. Moderate to severe anemia(HGB3 times the normal upper limit, Cr>3mg/dl); 17. People with allergies or known to be allergic to this medicine and ingredients; 18. Disability in the lower limbs or inability to cooperate for various reasons; 19. Women who are preparing for pregnancy, childbearing or breastfeeding in the last 3 months; 20. Participated in other clinical trials in the past 3 months; 21. The survival period not exceeding 3 months; 22. Patients could not complete the study or could not comply with the requirements of the study.

Design outcomes

Primary

Measure	Time frame
Peak VO2;GLS;UT;LAVI;	—

Secondary

Measure	Time frame
E/e';LVEF;	—

Countries

China

Contacts

Public ContactLi Bin

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

xxlibin2006@163.com+86 13752543757

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026